Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Sinusitis : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
References

Related Articles
Headache, Cluster

Headache, Migraine

Headache, Tension

Otitis Media




Patient Education
Click here for patient education.



Author: Elicia S Kennedy, MD, Clinical Assistant Professor, Department of Emergency Medicine, University of Arkansas for Medical Sciences

Elicia S Kennedy is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Editors: Daniel J Dire, MD, FACEP, FAAP, FAAEM, Clinical Associate Professor, Department of Emergency Medicine, University of Texas-Houston; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Mark W Fourre, MD, Program Director, Department of Emergency Medicine, Maine Medical Center; Associate Clinical Professor, Department of Surgery, University of Vermont School of Medicine; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital

Author and Editor Disclosure

Synonyms and related keywords: sinusitis, sinus inflammation, sinus infection, paranasal sinuses, inflammation of paranasal sinuses, infection of paranasal sinuses, nasopharyngeal flora, sinus disease, upper respiratory infections, URI, acute sinusitis, subacute sinusitis, chronic sinusitis, bacterial sinusitis, allergic rhinitis, severe allergic rhinitis, rhinoviral infection, maxillary sinusitis, Haemophilus influenzae, H influenzae, Streptococcus pneumoniae, S pneumoniae, Bacteroides, Peptostreptococcus, Fusobacterium, Moraxella catarrhalis, M catarrhalis, Staphylococcus aureus, S aureus, Candida, Aspergillus, Phycomycetes

Background

Sinusitis is the inflammation/infection of 1 or more paranasal sinuses and occurs with obstruction of the normal drainage mechanism. It is traditionally subdivided into acute (symptoms lasting <3 wk), subacute (symptoms lasting 3 wk to 3 mo), and chronic (symptoms lasting > 3 mo).

Pathophysiology

The paranasal sinuses, a part of the upper respiratory tract, are in direct communication with the nasopharynx. The sinuses are normally sterile. Because of the proximity to nasopharyngeal flora, obstruction can cause bacterial infection.

Diseases that obstruct drainage can result in a reduced ability of the paranasal sinuses to function normally. The sinus ostia may become occluded, leading to mucosal congestion. The mucociliary transport system becomes impaired, leading to more stagnation of secretion and epithelial damage, followed by decreased oxygen tension and subsequent bacterial growth.

Frequency

United States

An estimated more than 30 million patients in the United States have sinus disease. Upper respiratory infections (URIs) are one of the most common presentations in the ED. A viral infection associated with the common cold is the most frequent etiology of acute sinusitis. Only a small percentage (as low as 2%) of viral sinusitis cases are complicated by bacterial sinusitis. The challenge is to differentiate a simple URI and allergic rhinitis from sinusitis. Medical treatment is expensive, with an estimated $5 billion spent annually; another $60 billion is spent on surgical treatment each year.

Mortality/Morbidity

Sinusitis is rarely life threatening, but the close proximity of the paranasal sinuses to the central nervous system, the multiple fascial plains of the neck, and the associated venous and lymphatic channels can lead to serious complications.

Age

An estimated 5-10% of URIs in children are related to sinusitis, while up to 10% of URIs in adults are related to sinusitis. Sinusitis is rare in children younger than 1 year because the sinuses are poorly developed before that age.



History

  • Presentation of sinusitis is often nonspecific.
  • Patients may present with a persistent cold.
  • Most complaints are related to the involved sinus.
  • Common complaints are nasal congestion, purulent drainage, and facial pain with headache.
  • Pain is often exacerbated by leaning forward or any head movement.
  • Patients may complain of retro-orbital pain if the ethmoid sinus is involved.
  • Some patients complain of dental pain or alteration in smell.
  • In pediatric patients, most URIs last 5-7 days.
    • By 10 days, the URI almost always improves.
    • Most rhinoviral infections improve within 7-10 days so the complaint of persistent or worsening symptoms may indicate a developing bacterial sinusitis.
    • Pediatric patients may complain of a daytime cough and persistent nasal discharge.
    • Complaints of facial pain and headache are rare in children.

Physical

  • Purulent secretions in the middle meatus (highly predictive of maxillary sinusitis) may be seen using a nasal speculum and a directed light.
  • Fever is seen in fewer than 2% of individuals with sinusitis.
  • Facial tenderness to palpation is present.
  • Complete opacification of sinus on transillumination is present.
  • Partial opacification is a nonspecific finding, and it is not as reliable.

Causes

Acute sinusitis is usually bacterial in origin. A URI or severe allergic rhinitis leading to obstruction of the ostia and stasis of drainage often precedes it.

  • Haemophilus influenzae and Streptococcus pneumoniae are the organisms most commonly found in adults. In chronic sinusitis, the infecting organisms are variable, and a higher incidence of anaerobic organisms is seen (eg, Bacteroides, Peptostreptococcus, and Fusobacterium species).
  • In children, similar organisms are seen, with the addition of Moraxella catarrhalis. In older children and young adults, Staphylococcus aureus is an occasional finding.
  • In systemically impaired hosts, Candida, Aspergillus, and Phycomycetes may be the cause. Risk factors include the following: diabetes mellitus, cancer, hepatic disease, renal failure, burns, extreme malnutrition, and immunosuppressive diseases.



Headache, Cluster
Headache, Migraine
Headache, Tension
Otitis Media

Other Problems to be Considered

Dental infections
Periapical abscess
Upper respiratory tract infection



Imaging Studies

  • Sinus radiography: False-negative results occur in 40% of cases; mucosal thickening or air fluid levels may be seen.
  • A-mode ultrasonography has very little advantage over plain radiography.
  • Computerized tomography (CT): This very expensive imaging study is used extensively by otolaryngology (ENT) specialists and in the evaluation of chronic sinusitis. In some institutions, CT scanning is preferred as the initial study of choice. It is extremely sensitive, although it may tend to overdiagnose the disease. CT scans cannot distinguish between viral and bacterial infections.
  • Magnetic resonance imaging (MRI) can be used to demonstrate intracranial spread but is not as good as CT scanning in aiding in the diagnosis of acute sinusitis.
  • Radiographs or CT scanning is not mandatory in the diagnosis. Uncomplicated sinusitis is often diagnosed clinically, with studies reserved for complicated cases or patients who are nonresponsive to the usual therapies.



Emergency Department Care

Differentiate from other causes of nasal congestion. Treatment is aimed at blocking the inflammatory reactions that cause the symptoms, while antibiotics should be given to eliminate the infection in acute bacterial sinusitis.

  • Allergic rhinitis: Symptoms often are seasonal and may include the following: clear watery anterior and posterior nasal discharge, sneezing, and itchy eyes and nose.
  • Viral URI: Dry mucosa of nose and throat, malaise and myalgias, and occasional fever and chills may be present.
  • While in the ED, patients may obtain significant immediate relief with the administration of a nasal decongestant.
  • Warm compresses to the face give symptomatic relief.
  • Treatment to suppress the full development of symptoms, especially nasal fluid production, early on in viral rhinosinusitis includes first generation antihistamines, decongestants, and nonsteroidal anti-inflammatory drugs (NSAIDs).

Consultations

ENT consultation should be obtained in all patients with suspected CNS invasion or fungal infections. Consider referral to an ENT specialist for patients with subacute or chronic sinusitis.



The goal of uncomplicated sinusitis is to relieve obstruction. Antihistamines should be avoided, as they thicken secretions.

Drug Category: Nasal decongestants

These agents are used to loosen secretions for clearance.

Drug NameOxymetazoline (Afrin)
DescriptionApplied directly to mucous membranes, where it stimulates alpha-adrenergic receptors and causes vasoconstriction. Decongestion occurs without drastic changes in blood pressure, vascular redistribution, or cardiac stimulation.
Adult Dose2-3 sprays or 2-3 gtt of 0.05% solution in each nostril bid
Use for maximum of 3 d only; patients can become dependent
Pediatric Dose<6 years: 2-3 gtt of 0.025% solution in each nostril bid
>6 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; MAOI therapy
InteractionsHypotensive action of guanethidine may be reversed; concurrent administration with methyldopa may result in an increased vasopressor response; concurrent use of MAOIs and ephedrine may result in hypertensive crisis; pressor sensitivity to mixed-acting agents such as ephedrine may be increased; guanethidine potentiates effects of epinephrine and inhibits effects of ephedrine; phenothiazines may reverse action of nasal decongestants such as oxymetazoline; TCAs potentiate vasopressor response and may result in dysrhythmias
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in hyperthyroidism, coronary artery and ischemic heart disease, diabetes mellitus, increased intraocular pressure, or prostatic hypertrophy; because of increase in vasoconstriction, patients with hypertension may experience change in blood pressure; do not use topical decongestants for longer than 3-5 d

Drug NamePhenylephrine (Neo-Synephrine)
DescriptionA strong postsynaptic alpha-receptor stimulant with little effect on the beta-receptors of the heart.
Adult Dose1-2 sprays per nostril q3-4h
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; severe hypertension; ventricular tachycardia
InteractionsBretylium may potentiate action of vasopressors on adrenergic receptors, possibly resulting in arrhythmias; MAOIs may significantly enhance adrenergic effects of phenylephrine, and pressor response may be increased 2- to 3-fold; guanethidine may increase pressor response of direct-acting vasopressors, possibly resulting in severe hypertension
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in elderly patients, hyperthyroidism, myocardial disease, bradycardia, partial heart block, or severe arteriosclerosis; in hypovolemia, use is not a substitute for replacement of blood, fluids and electrolytes, and plasma (these should be restored promptly when loss has occurred)

Drug NamePseudoephedrine (Sudafed)
DescriptionStimulates vasoconstriction by directly activating the alpha-adrenergic receptors of the respiratory mucosa. Induces bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors. Available in 30- and 60-mg tablets, 30-mg/5 mL elixir, and in a sustained-release form 120 mg.
Adult Dose60 mg PO q4-6h; 120 mg SR q12h; not to exceed 240 mg/d
Pediatric Dose3-12 months: 3 gtt/kg q4-6h; not to exceed 4 doses/d
1-2 years: 7 gtt (0.2 mL)/kg q4-6h; not to exceed 4 doses/d
2-5 years: 15 mg PO q4-6h; not to exceed 60 mg/d
>5 years: 30 mg PO q4-6h; not to exceed 120 mg/d
ContraindicationsDocumented hypersensitivity; severe anemia; postural hypertension and hypotension; closed-angle glaucoma; head trauma; cerebral hemorrhage
InteractionsPropranolol, MAOIs, and sympathomimetic agents may increase toxicity of pseudoephedrine; methyldopa and reserpine may reduce effects of pseudoephedrine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in cardiovascular disease, diabetes mellitus, prostatic hypertrophy, and increased intraocular pressure

Drug Category: Antibiotics

Empiric coverage for H influenzae and S pneumoniae; in addition to M catarrhalis in children.

Drug NameTrimethoprim and sulfamethoxazole (Bactrim, Septra)
DescriptionInhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. By inhibiting the enzyme dihydrofolate reductase, the production of tetrahydrofolic acid decreases. These effects inhibit bacterial growth. Bacterial resistance appears to develop more slowly with this drug combination than with either drug alone. DOC along with AMP/CL. Available in elixir 40/200 per 5 mL, single strength (80/400) and double strength (160/800).
Adult Dose5 mg/kg (based on trimethoprim) IV q6h; 1 tab (double strength) PO bid
Pediatric Dose5 mL/10 kg/dose elixir PO bid
ContraindicationsDocumented hypersensitivity; megaloblastic anemia due to folate deficiency
InteractionsMay increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsDiscontinue at first appearance of rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholism, elderly persons, those receiving anticonvulsant therapy, or those with malabsorption syndrome); hemolysis may occur in G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation

Drug NameAmoxicillin and clavulanate (Augmentin)
DescriptionDrug combination that extends the antibiotic spectrum of penicillin to include bacteria normally resistant to beta-lactam antibiotics. Administer treatment for a minimum of 10 d. Available in 125-, 250-, and 500-mg tablets and in 125 and 250/5 mL elixir.
Adult Dose500 mg PO q12h; 250 mg PO q8h
Pediatric Dose30-40 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with warfarin or heparin increases risk of bleeding
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsGive for a minimum of 10 d to eliminate organism and prevent sequelae (endocarditis, and rheumatic fever); following treatment, perform cultures to confirm eradication of streptococci

Drug NameCefaclor (Ceclor)
DescriptionThese agents are indicated for the management of infections caused by susceptible mixed aerobic-anaerobic microorganisms. Proper dosage and route of administration should be determined by the condition of the patient, severity of the infection, and susceptibility of the causative organism.
Adult Dose250 mg PO tid
Pediatric Dose20-40 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity
InteractionsAlcoholic beverages consumed <72 h after taking cefaclor may produce disulfiramlike reactions; may increase hypoprothrombinemic effects of anticoagulants; coadministration with potent diuretics and aminoglycosides (eg, loop diuretics) may increase nephrotoxicity
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsReduce dosage by half if CrCl is 10-30 mL/min, and by one fourth if <10 mL/min; bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy

Drug NameAmoxicillin (Amoxil, Polymox)
DescriptionTreats infections caused by susceptible organisms and can be used as prophylaxis in minor procedures. An alternative therapy, but some resistant organisms are beginning to be seen in the US.
Adult Dose250-500 mg PO q8h; not to exceed 3 g/d
Pediatric Dose20-50 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity
InteractionsReduces the efficacy of oral contraceptives
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in renal impairment

Drug NameClarithromycin (Biaxin)
DescriptionReversibly binds to the P site of the 50S ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis by stimulating the dissociation of peptidyl tRNA from ribosomes.
Adult Dose250-500 mg PO q12h for 7-14 d
Pediatric Dose15 mg/kg PO divided bid
ContraindicationsDocumented hypersensitivity; coadministration of pimozide
InteractionsToxicity increases with coadministration of fluconazole, astemizole, and pimozide; clarithromycin effects decrease, and GI adverse effects may increase with coadministration of rifabutin or rifampin; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, omeprazole, carbamazepine, ergot alkaloids, triazolam, and HMG CoA-reductase inhibitors; cardiac arrhythmias may occur with coadministration of cisapride; plasma levels of certain benzodiazepines may increase, prolonging CNS depression; arrhythmias and increase in QTc intervals occur with disopyramide; coadministration with omeprazole may increase plasma levels of both agents
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsCoadministration with ranitidine or bismuth citrate is not recommended with CrCl <25 mL/min; give half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis; superinfections may occur with prolonged or repeated antibiotic therapies

Drug NameAzithromycin (Zithromax)
DescriptionAdvanced-generation macrolide works similarly to clarithromycin but with shorter dosage time.
Adult DoseDay 1: 500 mg PO
Days 2-5: 250 mg PO qd
Pediatric Dose<6 months: Not established
>6 months:
Day 1: 10 mg/kg PO once; not to exceed 500 mg/d
Days 2-5: 5 mg/kg PO qd; not to exceed 250 mg/d
ContraindicationsDocumented hypersensitivity; hepatic impairment; do not administer with pimozide
InteractionsMay increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsSite reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in hospitalized, geriatric, or debilitated patients

Drug NameLevofloxacin (Levaquin)
DescriptionThe S-enantiomer of ofloxacin, a fluoroquinolone antibiotic with improved activity against gram-positive organisms. Best used only in severe or refractory sinusitis.
Adult Dose500 mg PO qd for 7-21 d
Pediatric Dose<18 years: Not recommended
>18 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; levofloxacin reduces therapeutic effects of phenytoin; probenecid may increase levofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy

Drug NameCefpodoxime (Vantin)
DescriptionSecond-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have. Adds activity against P mirabilis, H influenzae, E coli, K pneumoniae, and M catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.
Adult Dose100-400 mg PO bid
Pediatric Dose10 mg/kg/d PO divided bid
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid increases effect; coadministration with furosemide and aminoglycosides increases nephrotoxic effects
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dosage in renal impairment

Drug NameCefuroxime (Ceftin, Zinacef)
DescriptionSecond-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have; adds activity against P mirabilis, H influenzae, E coli, K pneumoniae, and M catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.
Adult Dose250-500 mg PO bid
Pediatric Dose250 mg PO bid for 20 d
ContraindicationsDocumented hypersensitivity
InteractionsDisulfiramlike reactions may occur when alcohol is consumed within 72 h after taking cefuroxime; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics such as loop diuretics; coadministration with aminoglycosides increases nephrotoxic potential
PregnancyC - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
PrecautionsAdminister half dose if creatinine clearance is 10-30 mL/min and one-fourth dose if <10 mL/min; fungal and microorganism overgrowth may occur with prolonged therapy



Further Inpatient Care

  • Any patient showing evidence of extension of infection into the CNS should be admitted and evaluated by an ENT physician.

Further Outpatient Care

  • Prescribe antibiotic of choice and nasal decongestant. If an over-the-counter nasal spray (eg, Afrin) is used, warn the patient to use it no longer than 3 days to avoid any rebound phenomenon.
  • Instruct patients to drink a lot of fluids. Use of a humidifier or vaporizer helps in keeping secretions moist and loose.
  • Warm compresses to the face provide relief of pain. Pain medication may be prescribed, nonnarcotic or narcotic, at the discretion of the emergency physician.
  • Instruct patients to return to the ED or see their personal physician if high fever, visual symptoms, vomiting, lethargy, or any symptom indicating possible extension beyond the sinus cavities develops.

Complications

  • Chronic sinusitis
  • Osteomyelitis
  • Orbital cellulitis
  • Intracranial extension resulting in septic cavernous thrombosis

Prognosis

  • The prognosis is generally good with appropriate treatment.



  • American Academy of Pediatrics. Clinical practice guideline: management of sinusitis. Pediatrics. Sep 2001;108(3):798-808. [Medline].
  • Benninger MS, Sedory Holzer SE, Lau J. Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: summary of the Agency for Health Care Policy and Research evidence-based report. Otolaryngol Head Neck Surg. Jan 2000;122(1):1-7. [Medline].
  • Brook I. Microbiology and management of sinusitis. J Otolaryngol. Aug 1996;25(4):249-56. [Medline].
  • Chow JM. The diagnosis and management of sinusitis. Compr Ther. 1995;21(2):74-9. [Medline].
  • Duncavage JA. Management of sinusitis. Compr Ther. Apr 1996;22(4):211-6. [Medline].
  • Osguthorpe JD, Hadley JA. Rhinosinusitis. Current concepts in evaluation and management. Med Clin North Am. Jan 1999;83(1):27-41, vii-viii. [Medline].
  • Piccirillo JF. Clinical practice. Acute bacterial sinusitis. N Engl J Med. Aug 26 2004;351(9):902-10. [Medline].
  • Snow V, Mottur-Pilson C, Gonzales R. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med. Mar 20 2001;134(6):518-20. [Medline].
  • Williams JW, Simel DL. Does this patient have sinusitis? Diagnosing acute sinusitis by history and physical examination. JAMA. Sep 8 1993;270(10):1242-6. [Medline].

Sinusitis excerpt

Article Last Updated: Aug 8, 2007